Harmony Biosciences Hldgs Analyst Price Targets

Wall Street analyst price targets and consensus rating for Harmony Biosciences Hldgs (HRMY).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

8Buy

3Hold

2Sell

Consensus RatingOutperform# Analysts13Avg. Consensus PT$48Upside to Avg. PT+25.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	Needham	Ami Fadia	Maintained	Buy	$50
Oct 13, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$55
Oct 12, 2026	Needham	Ami Fadia	Maintained	Buy	$50
Aug 26, 2026	Wolfe Research	Rudy Li	Initiate	Outperform	$60
Aug 5, 2026	Truist Securities	Danielle Brill	PT Raise	Hold	$29→$34
Aug 4, 2026	Needham	Ami Fadia	PT Raise	Buy	$45→$50
Jul 31, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$50→$51
Jul 16, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$55
Jun 30, 2026	Deutsche Bank	David Hoang	PT Raise	Hold	$30→$36
May 8, 2026	Truist Securities	Danielle Brill	PT Raise	Hold	$25→$29
Feb 25, 2026	UBS	So Youn Shim	PT Cut	Neutral	$46→$36
Feb 25, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$55
Feb 25, 2026	B of A Securities	Jason Gerberry	PT Cut	Underperform	$32→$28
Feb 25, 2026	Needham	Ami Fadia	PT Cut	Buy	$46→$44
Feb 11, 2026	UBS	Ashwani Verma	Downgrade	Buy→Neutral	$43→$46
Jan 8, 2026	Truist Securities	Danielle Brill	PT Cut	Buy	$48→$45
Dec 1, 2025	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$39→$46
Nov 24, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$55
Nov 24, 2025	Needham	Ami Fadia	Maintained	Buy	$42
Nov 6, 2025	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$36→$39

Analyst Ratings News

PRO
Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $50 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $55 price target.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $50 price target.

Benzinga Newsdesk

This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Consider ACMR stock: analysts' thoughts

Avi Kapoor

PRO
Wolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60

Wolfe Research analyst Rudy Li initiates coverage on Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $60.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $34

Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold and raises the price target from $29 to $34.

Benzinga Newsdesk

Harmony Biosciences Holdings Inc

Harmony Biosciences Hldgs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target

PRO
Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PRO
Wolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60

PRO
Truist Securities Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $34

People Also Watch

People Also Watch

Harmony Biosciences Holdings Inc

Harmony Biosciences Hldgs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRONeedham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

PROHC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target

PRONeedham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PROWolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60

PROTruist Securities Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $34

People Also Watch

People Also Watch

PRO
Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target

PRO
Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

PRO
Wolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60

PRO
Truist Securities Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $34